<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942888</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20160350H</org_study_id>
    <nct_id>NCT02942888</nct_id>
  </id_info>
  <brief_title>The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition</brief_title>
  <acronym>NAD</acronym>
  <official_title>The Effects of NAD on Brain Function and Cognition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South Texas Veterans Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of Niagen (nicotinamide riboside,
      vitamin B3), on NAD levels, brain function including cognition and blood flow in people
      diagnosed with mild cognitive impairment (MCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Niagen is a patented formula which is the first and only commercially available form of
      Nicotinamide Riboside (NR). It has been proven in basic science studies as a highly effective
      NAD booster, but it also works as a vitamin B3 supplement. NAD helps pass energy from glucose
      to other pathways in the cell. Niagen (Nicotinamide Riboside, vitamin B3) is one of the most
      effective NAD+ precursors to support cellular health.

      The purpose of this study is to determine the effects of Niagen (nicotinamide riboside,
      vitamin B3), on NAD levels, brain function including cognition and blood flow in people
      diagnosed with mild cognitive impairment (MCI).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cognitive Assessment - Montreal Cognitive Assessment (MoCA) - from baseline at 10 weeks</measure>
    <time_frame>10 weeks</time_frame>
    <description>MoCA Value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cerebral blood flow from baseline at 10 weeks</measure>
    <time_frame>10 weeks</time_frame>
    <description>functional Magnetic Resonance Imaging (fMRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma NAD from baseline at 10 weeks</measure>
    <time_frame>10 weeks</time_frame>
    <description>Plasma NAD level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Performance - Short Physical Performance Battery (SPPB) - from baseline at 10 weeks</measure>
    <time_frame>10 weeks</time_frame>
    <description>SPPB Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Performance - Instrumental Activities of Daily Living (IADLs) - from baseline at 10 weeks</measure>
    <time_frame>10 weeks</time_frame>
    <description>IADL Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in endothelial function from baseline at 10 weeks</measure>
    <time_frame>10 weeks</time_frame>
    <description>Arterial Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Assessment - Geriatric Depression Scale (GDS) - from baseline at 10 weeks</measure>
    <time_frame>10 weeks</time_frame>
    <description>GDS Value (&gt;/= 5 is abnormal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Assessment - Geriatric Anxiety Scale (GAS) - from baseline at 10 weeks</measure>
    <time_frame>10 weeks</time_frame>
    <description>GAS Value (Raw score 1 -30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Assessment - Clock Drawing Task Protocol (CLOX) - from baseline at 10 weeks</measure>
    <time_frame>10 weeks</time_frame>
    <description>CLOX Value (Score 0-15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Assessment - Executive Interview (EXIT) - from baseline at 10 weeks</measure>
    <time_frame>10 weeks</time_frame>
    <description>EXIT Value (Score 0-50)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognitive Assessment - Test of Auditory Processing Skills (TAPS) - from baseline at 10 weeks</measure>
    <time_frame>10 weeks</time_frame>
    <description>TAPS Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physical Performance - Grip Strength - from baseline at 10 weeks</measure>
    <time_frame>10 weeks</time_frame>
    <description>Grip Strength (kgs)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>NAD</condition>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10). Controls will receive sugar pills.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10).Controls will receive sugar pills.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nicotinamide riboside</intervention_name>
    <description>Oral administration of Niagen ramp up 250mg to 1g/day as tolerated</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>MCI</arm_group_label>
    <other_name>Niagen; ChromaDex, Inc.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sugar Pill</intervention_name>
    <description>This is a placebo compounded by ChromaDex, Inc.</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>MCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously diagnosed with MCI based on inclusion criteria of Texas Alzheimer's
             Research Care and Consortium (TARCC) study (IRB: HSC20090535H). We are enrolling both
             genders, all races and ethnic groups.

        Exclusion Criteria:

          -  Previously considered as healthy individuals without a MCI or Alzheimer's disease
             diagnosis based on exclusion criteria of the TARCC study (IRB: HSC20090535H).

          -  Neurological, psychiatric or active systemic medical disease

          -  Diabetes

          -  Moderate or severe depression and/or anxiety as determined the Geriatric Depression
             Scale (GDS) and the Geriatric Anxiety Scale (GAS), respectively

          -  Diagnosis of dementia

          -  Hearing, vision, motor or language deficits

          -  Alcohol or drug abuse

          -  Implantation of metal devices

          -  Administration of Alzheimer's drugs, anticholinergics, neuroleptics, anticonvulsants,
             opiates, systemic steroids, and mood-stabilizers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Becky Powers, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center in San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Becky Powers, M.D.</last_name>
    <phone>210 617-5197</phone>
    <email>PowersB3@uthscsa.edu; becky.powers@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miranda E Orr, Ph.D.</last_name>
    <phone>210 275-8976</phone>
    <email>orrm3@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>South Texas Veterans Healthcare System (STVHCS)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Hecht</last_name>
      <phone>210-617-5300</phone>
      <phone_ext>14654</phone_ext>
      <email>Joan.hecht@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Powers, MD</last_name>
      <phone>210-617-5179</phone>
      <email>Becky.powers@va.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Becky Powers</investigator_full_name>
    <investigator_title>Assistant Professor, Medicine</investigator_title>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>MCI</keyword>
  <keyword>NAD</keyword>
  <keyword>nicotinamide riboside</keyword>
  <keyword>aging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

